Adial Pharmaceuticals to appoint Celia Economides as CFO
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $ADIL +0.51% in the latest session.
- Timing: It landed before the opening bell — early risers had it with their coffee, and the next session was the first that could react.
Where the stock stands
$ADIL last changed hands at $3.94, +0.51% on the session, 59% below its 52-week high of $9.50 and 201% above its low of $1.31 — a little below the middle of the range. Over the year it has ranged 625% from low to high: a very wide band — this one has spent the year on a roller coaster, and big swings are business as usual. These are latest-session quotes, not live prices — the live tape is on the $ADIL page.
How much coverage it is getting
This is the only story Wook has logged on $ADIL in the last 30 days — a quiet name that just got a headline. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$ADIL earnings in 17 days. These were on the calendar before this story and are not caused by it.
What to watch next
For the receipts, the $ADIL page has the full chart, the filings and the valuation model these figures come from. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $ADIL is from its high, or how this week's coverage compares.
How this analysis was made
Seeking Alpha published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $ADIL. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.